JAHA:血管生成标志物对慢性高血压孕妇的预后价值

2021-08-29 MedSci原创 MedSci原创

疑似合并先兆子痫妇女的血管生成标志物失衡可以预测分娩。

与血压正常的女性相比,慢性高血压女性患先兆子痫的风险增加了5到6倍。血管生成标志物,尤其是可溶性fms样激酶1(sFlt-1)和胎盘生长因子(PlGF),被确定为临床上先兆子痫发生发展有用的预测标志物。

近日,心血管疾病领域权威杂志JAHA上发表了一篇研究文章,研究人员旨在评估sFlt-1/PlGF比值对慢性高血压合并先兆子痫女性分娩的预测价值。


这项回顾性研究纳入了142名患有慢性高血压和疑似合并先兆子痫的女性。27名妇女(19.0%)仅因孕妇并发症而分娩,17名妇女(12.0%)主要因胎儿并发症而分娩,98名妇女(69.0%)因其他原因分娩。与因其他原因分娩妇女相比,因孕妇并发症和胎儿并发症而分娩的女性具有更高的sFlt-1/PlGF比值(中位数分别为99.9和120.2 vs. 7.3,P<0.001)和更低的PlGF水平(中位数73.6和53.3 vs 320.0pg)/mL,两者的P<0.001)。

SFlt-1/PlGF比值和PlGF是由于先兆子痫而分娩的较强预测因子,无论是孕妇还是胎儿的并发症所致(P<0.05)。半数血管生成失衡(sFlt-1/PlGF比值≥85或PlGF水平<100pg/mL)的女性在出现孕肚或胎儿并发症1.6周(95%CI为1.0-2.4周)内分娩。
 
由此可见,疑似合并先兆子痫妇女的血管生成标志物失衡可以预测分娩。

原始出处:

Julia Binder.et al.Prognostic Value of Angiogenic Markers in Pregnant Women With Chronic Hypertension.JAHA.2021.https://www.ahajournals.org/doi/10.1161/JAHA.120.020631

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1841728, encodeId=aad51841e28c4, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Jul 26 17:21:09 CST 2022, time=2022-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687168, encodeId=03fe168e1685d, content=<a href='/topic/show?id=113e89e0118' target=_blank style='color:#2F92EE;'>#血管生成标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89701, encryptionId=113e89e0118, topicName=血管生成标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd3d28331356, createdName=ms3153534357578991, createdTime=Wed Jan 19 22:21:09 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803880, encodeId=74931803880ad, content=<a href='/topic/show?id=80a2e6071cf' target=_blank style='color:#2F92EE;'>#管生成标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76071, encryptionId=80a2e6071cf, topicName=管生成标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Mon Aug 08 15:21:09 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268618, encodeId=5fdb126861897, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Aug 31 07:21:09 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385254, encodeId=0d2c138525480, content=<a href='/topic/show?id=dc121001e22d' target=_blank style='color:#2F92EE;'>#预后价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100172, encryptionId=dc121001e22d, topicName=预后价值)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Tue Aug 31 07:21:09 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551693, encodeId=d020155169349, content=<a href='/topic/show?id=c4e253e3568' target=_blank style='color:#2F92EE;'>#慢性高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53735, encryptionId=c4e253e3568, topicName=慢性高血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe9e14213265, createdName=shenxlcyp, createdTime=Tue Aug 31 07:21:09 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012585, encodeId=807610125850c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/ee9a7b4ae703425dacf3380496b66f06/7430b424e22b4707acd3f2dd9224ffab.jpg, createdBy=bfc55468611, createdName=ms4000000080465939, createdTime=Sun Aug 29 16:36:12 CST 2021, time=2021-08-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1841728, encodeId=aad51841e28c4, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Jul 26 17:21:09 CST 2022, time=2022-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687168, encodeId=03fe168e1685d, content=<a href='/topic/show?id=113e89e0118' target=_blank style='color:#2F92EE;'>#血管生成标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89701, encryptionId=113e89e0118, topicName=血管生成标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd3d28331356, createdName=ms3153534357578991, createdTime=Wed Jan 19 22:21:09 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803880, encodeId=74931803880ad, content=<a href='/topic/show?id=80a2e6071cf' target=_blank style='color:#2F92EE;'>#管生成标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76071, encryptionId=80a2e6071cf, topicName=管生成标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Mon Aug 08 15:21:09 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268618, encodeId=5fdb126861897, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Aug 31 07:21:09 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385254, encodeId=0d2c138525480, content=<a href='/topic/show?id=dc121001e22d' target=_blank style='color:#2F92EE;'>#预后价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100172, encryptionId=dc121001e22d, topicName=预后价值)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Tue Aug 31 07:21:09 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551693, encodeId=d020155169349, content=<a href='/topic/show?id=c4e253e3568' target=_blank style='color:#2F92EE;'>#慢性高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53735, encryptionId=c4e253e3568, topicName=慢性高血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe9e14213265, createdName=shenxlcyp, createdTime=Tue Aug 31 07:21:09 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012585, encodeId=807610125850c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/ee9a7b4ae703425dacf3380496b66f06/7430b424e22b4707acd3f2dd9224ffab.jpg, createdBy=bfc55468611, createdName=ms4000000080465939, createdTime=Sun Aug 29 16:36:12 CST 2021, time=2021-08-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1841728, encodeId=aad51841e28c4, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Jul 26 17:21:09 CST 2022, time=2022-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687168, encodeId=03fe168e1685d, content=<a href='/topic/show?id=113e89e0118' target=_blank style='color:#2F92EE;'>#血管生成标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89701, encryptionId=113e89e0118, topicName=血管生成标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd3d28331356, createdName=ms3153534357578991, createdTime=Wed Jan 19 22:21:09 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803880, encodeId=74931803880ad, content=<a href='/topic/show?id=80a2e6071cf' target=_blank style='color:#2F92EE;'>#管生成标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76071, encryptionId=80a2e6071cf, topicName=管生成标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Mon Aug 08 15:21:09 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268618, encodeId=5fdb126861897, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Aug 31 07:21:09 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385254, encodeId=0d2c138525480, content=<a href='/topic/show?id=dc121001e22d' target=_blank style='color:#2F92EE;'>#预后价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100172, encryptionId=dc121001e22d, topicName=预后价值)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Tue Aug 31 07:21:09 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551693, encodeId=d020155169349, content=<a href='/topic/show?id=c4e253e3568' target=_blank style='color:#2F92EE;'>#慢性高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53735, encryptionId=c4e253e3568, topicName=慢性高血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe9e14213265, createdName=shenxlcyp, createdTime=Tue Aug 31 07:21:09 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012585, encodeId=807610125850c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/ee9a7b4ae703425dacf3380496b66f06/7430b424e22b4707acd3f2dd9224ffab.jpg, createdBy=bfc55468611, createdName=ms4000000080465939, createdTime=Sun Aug 29 16:36:12 CST 2021, time=2021-08-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1841728, encodeId=aad51841e28c4, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Jul 26 17:21:09 CST 2022, time=2022-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687168, encodeId=03fe168e1685d, content=<a href='/topic/show?id=113e89e0118' target=_blank style='color:#2F92EE;'>#血管生成标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89701, encryptionId=113e89e0118, topicName=血管生成标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd3d28331356, createdName=ms3153534357578991, createdTime=Wed Jan 19 22:21:09 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803880, encodeId=74931803880ad, content=<a href='/topic/show?id=80a2e6071cf' target=_blank style='color:#2F92EE;'>#管生成标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76071, encryptionId=80a2e6071cf, topicName=管生成标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Mon Aug 08 15:21:09 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268618, encodeId=5fdb126861897, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Aug 31 07:21:09 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385254, encodeId=0d2c138525480, content=<a href='/topic/show?id=dc121001e22d' target=_blank style='color:#2F92EE;'>#预后价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100172, encryptionId=dc121001e22d, topicName=预后价值)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Tue Aug 31 07:21:09 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551693, encodeId=d020155169349, content=<a href='/topic/show?id=c4e253e3568' target=_blank style='color:#2F92EE;'>#慢性高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53735, encryptionId=c4e253e3568, topicName=慢性高血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe9e14213265, createdName=shenxlcyp, createdTime=Tue Aug 31 07:21:09 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012585, encodeId=807610125850c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/ee9a7b4ae703425dacf3380496b66f06/7430b424e22b4707acd3f2dd9224ffab.jpg, createdBy=bfc55468611, createdName=ms4000000080465939, createdTime=Sun Aug 29 16:36:12 CST 2021, time=2021-08-29, status=1, ipAttribution=)]
    2021-08-31 zhaohui6731
  5. [GetPortalCommentsPageByObjectIdResponse(id=1841728, encodeId=aad51841e28c4, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Jul 26 17:21:09 CST 2022, time=2022-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687168, encodeId=03fe168e1685d, content=<a href='/topic/show?id=113e89e0118' target=_blank style='color:#2F92EE;'>#血管生成标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89701, encryptionId=113e89e0118, topicName=血管生成标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd3d28331356, createdName=ms3153534357578991, createdTime=Wed Jan 19 22:21:09 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803880, encodeId=74931803880ad, content=<a href='/topic/show?id=80a2e6071cf' target=_blank style='color:#2F92EE;'>#管生成标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76071, encryptionId=80a2e6071cf, topicName=管生成标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Mon Aug 08 15:21:09 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268618, encodeId=5fdb126861897, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Aug 31 07:21:09 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385254, encodeId=0d2c138525480, content=<a href='/topic/show?id=dc121001e22d' target=_blank style='color:#2F92EE;'>#预后价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100172, encryptionId=dc121001e22d, topicName=预后价值)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Tue Aug 31 07:21:09 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551693, encodeId=d020155169349, content=<a href='/topic/show?id=c4e253e3568' target=_blank style='color:#2F92EE;'>#慢性高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53735, encryptionId=c4e253e3568, topicName=慢性高血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe9e14213265, createdName=shenxlcyp, createdTime=Tue Aug 31 07:21:09 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012585, encodeId=807610125850c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/ee9a7b4ae703425dacf3380496b66f06/7430b424e22b4707acd3f2dd9224ffab.jpg, createdBy=bfc55468611, createdName=ms4000000080465939, createdTime=Sun Aug 29 16:36:12 CST 2021, time=2021-08-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1841728, encodeId=aad51841e28c4, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Jul 26 17:21:09 CST 2022, time=2022-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687168, encodeId=03fe168e1685d, content=<a href='/topic/show?id=113e89e0118' target=_blank style='color:#2F92EE;'>#血管生成标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89701, encryptionId=113e89e0118, topicName=血管生成标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd3d28331356, createdName=ms3153534357578991, createdTime=Wed Jan 19 22:21:09 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803880, encodeId=74931803880ad, content=<a href='/topic/show?id=80a2e6071cf' target=_blank style='color:#2F92EE;'>#管生成标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76071, encryptionId=80a2e6071cf, topicName=管生成标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Mon Aug 08 15:21:09 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268618, encodeId=5fdb126861897, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Aug 31 07:21:09 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385254, encodeId=0d2c138525480, content=<a href='/topic/show?id=dc121001e22d' target=_blank style='color:#2F92EE;'>#预后价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100172, encryptionId=dc121001e22d, topicName=预后价值)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Tue Aug 31 07:21:09 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551693, encodeId=d020155169349, content=<a href='/topic/show?id=c4e253e3568' target=_blank style='color:#2F92EE;'>#慢性高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53735, encryptionId=c4e253e3568, topicName=慢性高血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe9e14213265, createdName=shenxlcyp, createdTime=Tue Aug 31 07:21:09 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012585, encodeId=807610125850c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/ee9a7b4ae703425dacf3380496b66f06/7430b424e22b4707acd3f2dd9224ffab.jpg, createdBy=bfc55468611, createdName=ms4000000080465939, createdTime=Sun Aug 29 16:36:12 CST 2021, time=2021-08-29, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1841728, encodeId=aad51841e28c4, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Jul 26 17:21:09 CST 2022, time=2022-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687168, encodeId=03fe168e1685d, content=<a href='/topic/show?id=113e89e0118' target=_blank style='color:#2F92EE;'>#血管生成标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89701, encryptionId=113e89e0118, topicName=血管生成标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd3d28331356, createdName=ms3153534357578991, createdTime=Wed Jan 19 22:21:09 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803880, encodeId=74931803880ad, content=<a href='/topic/show?id=80a2e6071cf' target=_blank style='color:#2F92EE;'>#管生成标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76071, encryptionId=80a2e6071cf, topicName=管生成标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Mon Aug 08 15:21:09 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268618, encodeId=5fdb126861897, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Aug 31 07:21:09 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385254, encodeId=0d2c138525480, content=<a href='/topic/show?id=dc121001e22d' target=_blank style='color:#2F92EE;'>#预后价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100172, encryptionId=dc121001e22d, topicName=预后价值)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Tue Aug 31 07:21:09 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551693, encodeId=d020155169349, content=<a href='/topic/show?id=c4e253e3568' target=_blank style='color:#2F92EE;'>#慢性高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53735, encryptionId=c4e253e3568, topicName=慢性高血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe9e14213265, createdName=shenxlcyp, createdTime=Tue Aug 31 07:21:09 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012585, encodeId=807610125850c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/ee9a7b4ae703425dacf3380496b66f06/7430b424e22b4707acd3f2dd9224ffab.jpg, createdBy=bfc55468611, createdName=ms4000000080465939, createdTime=Sun Aug 29 16:36:12 CST 2021, time=2021-08-29, status=1, ipAttribution=)]
    2021-08-29 ms4000000080465939

    学习了

    0

相关资讯

Heart:C反应蛋白在先天性心脏病成人中的预后价值

Hs-CRP对死亡或HF的预后价值增加,超过NT-proBNP和hs-肌钙蛋白T。Hs-CRP在HF或死亡发生前升高,这些结果支持炎症在ACHD患者临床恶化中的作用。

JAHA:法洛四联症患儿术前淋巴细胞**计数的预后价值

法洛四联症(TOF)是最常见的紫绀型先天性心脏病,术前较低的ALC是TOF患儿预后不良的独立预测因素。

JAHA:腰肌质量指数在非ST段抬高型心肌梗死患者中的预后价值

由PMI定义的肌肉消瘦,是预测非ST段抬高型心肌梗死患者未来心血管预后简单而有用的客观指标。

Crit Care:床旁肺部超声评分对COVID-19患者的预后价值

床旁肺部超声(LUS)已成为一种有用的无创性检查手段,可用于检测COVID-19患者有无肺部受累并监测其变化。但是,LUS评分在COVID-19患者中的临床意义尚未明确。近日,危重病医学领域权威杂志C

JAHA:腹主动脉钙化的预后价值

高风险人群,例如伴有AAC的老年人和慢性肾脏疾病人群,未来发生心血管事件的风险大大增加,患者预后也较差。分析AAC的相关信息可以帮助临床医生更好地了解和管理患者的心血管风险。

Heart:骨密度对女性不良心血管疾病的预后价值如何?

女性BMD评估可为ASCVD事件提供了独立且额外预后价值,因此可以改善女性的风险分层。